UnknownNot Applicable

The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection

Egypt24 participantsStarted 2024-02-01

Plain-language summary

The aim of this study is to study the role of adjuvant Albendazole after pulmonary hydatid cyst resection versus placebo in reducing recurrence with a short- term follow-up of six months.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. All patients regardless of age with pulmonary hydatid disease requiring surgical resection.
✓. Patients achieving complete resection of pulmonary hydatid disease.
✓. Patients with no extra pulmonary hydatid disease.
✓. Patients who have received preoperative albendazole.

Exclusion criteria

✕. Patients with extra pulmonary hydatid disease requiring treatment after pulmonary resection.
✕. Patients with incomplete resection of pulmonary hydatid disease.
✕. Patients with pulmonary hydatid disease not amenable for resection.
✕. Patients with hypersensitivity to Albendazole.
✕. Patients with liver dysfunction.
✕. Patients refusing to be enrolled in the study.

What they're measuring

Recurrence of pulmonary hydatid disease

Timeframe: six months

Trial details

NCT IDNCT06483880

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Pulmonary Hydatid Cyst trials